Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
148.36
+2.86 (1.97%)
At close: May 6, 2026, 4:00 PM EDT
147.84
-0.52 (-0.35%)
After-hours: May 6, 2026, 7:59 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.52B in the quarter ending March 31, 2026, a decrease of -0.70%. This brings the company's revenue in the last twelve months to $56.58B, up 6.31% year-over-year. In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth.
Revenue (ttm)
$56.58B
Revenue Growth
+6.31%
P/S Ratio
5.01
Revenue / Employee
$751,697
Employees
75,267
Market Cap
283.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
| Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Sanofi | 54.60B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.48B |
NVS News
- 10 hours ago - This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout - Investor's Business Daily
- 1 day ago - Novartis to cut 220 jobs as it closes German site - Reuters
- 2 days ago - ‘I’d lost my identity.’ How this exec recovered from redundancy - The Australian Financial Review
- 5 days ago - November 20th Options Now Available For Novartis (NVS) - Nasdaq
- 6 days ago - Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100 - GuruFocus
- 6 days ago - Novartis (NVS) Expands Manufacturing with New Facility in North Carolina - GuruFocus
- 7 days ago - IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - Business Upturn
- 7 days ago - Noteworthy ETF Inflows: AVDE, SHEL, HSBC, NVS - Nasdaq